CAMBRIDGE, Mass. & SUMMIT, N.J.--(BUSINESS WIRE)--Acceleron Pharma Inc. (NASDAQ:XLRN) and Celgene Corporation (NASDAQ: CELG), today announced preliminary results from an ongoing long-term Phase 2 extension study with luspatercept in patients with lower risk myelodysplastic syndromes (MDS) at the 21st Congress of the European Hematology Association (EHA) in Copenhagen, Denmark. Results highlighted in an oral presentation showed that 51% of patients with lower risk MDS treated with luspatercept (
![]()
↧